AdvaMed® Statement on President’s Reciprocal Tariff Pause
WASHINGTON – Today AdvaMed, the MedTech Association®, released the following statement from President and CEO Scott Whitaker:
“We are encouraged by the President’s announcement of a 90-day pause on reciprocal tariffs. This is an important decision that restores some short-term certainty to global markets, including the American medtech industry, which is number one globally.
“Moving forward, we will spend the next 90 days working with the President and his senior team to ensure the unique role of the medtech industry is protected, with the hope that the ultimate outcome is ‘zero for zero’ tariffs on medtech with all key trading partners.”
Related Reading
News / Government & Legislative Affairs / Regulatory Affairs
AdvaMed Welcomes Key Developments in MDUFA VI Process
July 8, 2026
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today welcomed next steps in the Medical Device User Fee Amendments reauthorization process following clearance by the White House Office of Management and Budget of the draft MDUFA VI agreement.
News / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Health Access / Regulatory Affairs
AdvaMed Statement on the Klomp Nomination
June 26, 2026
WASHINGTON—Scott Whitaker, president and CEO of AdvaMed, the largest trade association representing medtech innovators, posted his statement on LinkedIn regarding the nomination of Chris Klomp as deputy secretary of the Department of Health and Human Services.
Blog / Coverage & Payment / Digital Health / Government & Legislative Affairs / Health Access / Regulatory Affairs
Essential Tremor Treatment: A Sensible Solution, Possibly Driven Out of Reach
June 22, 2026
Millions of Americans have the neurological condition essential tremor. Often, that means their hand shakes so badly, they can’t hold a pen, fork, or glass of water. Every activity of daily living is compromised, day and night.
Blog / Coverage & Payment / Digital Health / Government & Legislative Affairs / Health Access / Medical Imaging
AdvaMed-Supported State Legislative Wins Advance Patient Access Across the U.S.
June 1, 2026
Millions of patients’ lives are improved every day because of advancements in medical technology. But too often, gaps in coverage and access prevent patients from benefiting from the safe, effective, and innovative technologies that can help detect disease earlier, improve treatment, and support better outcomes.
That is why AdvaMed’s 2026 Patients First Agenda focuses on supporting policies that put patients at the center of health care. Across the country, AdvaMed works alongside patient advocacy group partners to help address gaps in access and coverage for critical medical technologies and bring innovative care to patients and families when they need it most.
Blog / Emerging Policy Response Resources / Global & Trade / Tariffs
IEEPA Tariff Refunds Summary – What MedTech Companies Need to Know
April 29, 2026
After the Supreme Court struck down IEEPA tariffs, CBP launched the CAPE system to process refunds. Here’s what importers need to know about eligibility, submission, and timing.
Blog / Coverage & Payment / Government & Legislative Affairs / Health Access / Regulatory Affairs
A Policy Win for Maternal Health Innovation Through FDA–CMS Collaboration
April 27, 2026
The United States faces a maternal health crisis demanding urgent action. The U.S. has the worst maternal outcomes among high income nations. Our maternal mortality rates far exceed peer countries’, despite the highest per capita health care spending. Protecting mothers and improving birth outcomes provides an important opportunity for bipartisan priority leadership.
Resource / AdvaMed Advancements / Emerging Policy Response Resources / Global & Trade / Tariffs
AdvaMed® Advancements: Q1 2026 Report
April 24, 2026
Explore AdvaMed®’s Q1 2026 report on medtech policy, regulatory trends, reimbursement, and advocacy driving innovation and patient access.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
IEEPA Tariff Refunds Are Coming: What Medtech Needs to Know
Now On-Demand
The U.S. Supreme Court recently marked a significant shift in the tariff landscape, learn what that means for your organization.